+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Respiratory Inhalers Market - Global Outlook and Forecast 2020-2025

  • PDF Icon


  • 219 Pages
  • September 2020
  • Region: Global
  • Arizton
  • ID: 5141751
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Respiratory Inhalers Market Report

The respiratory inhalers market by revenue is expected to grow at a CAGR of over 9% during the period 2019-2025.

The global respiratory inhalers market is one of the steadily growing segments in the medical devices market. The steady growth can be attributed to the growing prevalence of asthma, COPD, and cystic fibrosis and the outbreak of the COVID-19 pandemic. The prevalence of COPD and other respiratory disorders demanding inhalers has increased at a significant rate over the last few years across the globe. According to the WHO, COPD is expected to emerge as the third leading cause of death across the world by 2025. The increasing incidence of respiratory diseases and the growing demand for treatment options for respiratory disorders are fueling the market growth of therapeutic respiratory care devices such as inhalers. Further, the presence of established infrastructure in several countries of North America, Europe, and APAC, coupled with the availability of well-developed technologies that allow early implementation of advanced inhalation technologies, increases the demand for inhalers. Favorable government initiatives in emerging economies toward improvising standard healthcare infrastructure and increased focus on healthcare expenditure are also aiding to focus on offering high-quality healthcare services.

The following factors are likely to contribute to the growth of the respiratory inhalers market during the forecast period:
  • Increase in Usage of Smart Inhaler
  • Introduction of Soft Mist Inhalers
  • Increase in Target Population
  • Surge in Inhalers Usage due to COVID-19

The study considers the present scenario of the respiratory inhalers market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.

Global Respiratory Inhalers Market Segmentation

The global respiratory inhalers market research report includes a detailed segmentation by products, patient, distribution channel, and geography. The metered dosage inhaler segment is expected to over 2.5 billion by 2025 due to the outbreak of COVID-19, which has led to the increased usage of inhalers among respiratory disease patients. Pressurized metered dosage inhalers (pMDIs) and dry-powder inhalers (DPIs) are commonly used among end-users. pMDIs are mostly used among developing and underdeveloped countries due to their low price and easy availability in pharmacies. DPI, breath-actuated inhalers, and soft mist inhalers are widely used in developed countries such as the US, the UK, and Germany as the treatment in the countries are covered under insurance and reimbursement policies. Developed countries are the matured market, where most advanced versions of smart inhalers are used among people. MDIs are considered as the first line of treatment for major respiratory disorders such as COPD and Asthma. However, a major challenge faced by the segment is the lack of awareness among patients and healthcare providers regarding the correct usage of MDIs.

The respiratory inhalers market is segmented into pediatric and adults age groups. In. 2019, the adult segment accounted for the share of 68%, and the pediatric population constituted a share of 32% in the respiratory inhalers market. The adult population is widely exposed to several environmental risk factors such as air and workplace pollutions and the consumption of tobacco. This contributes to the high share of the adult population in the market. While the prevalence of asthma is increasing in several countries, multiple factors are affecting the incidence of asthma in the adult population. With the eruption of the COVID-19 pandemic, the number of adults infected is higher than pediatric and neonates populations. Therefore, the demand for inhalers has gone drastically up across the globe due to the spread of the virus.

The hospital pharmacy segment accounted for a share of 47%. Hospitals are the first point of contact for the evaluation and treatment of respiratory diseases such as asthma and COPD. As the number of hospitals has grown over the period, the count of hospital pharmacies has also increased. In the middle- and low-income countries, several smaller clinics, nursing homes have tie-ups with hospital pharmacies to refer patients to purchase branded medical devices for the usage.

Segmentation by Products
  • Metered Dosage Inhaler
  • Dry Powder Inhaler

Segmentation by Patient
  • Adults
  • Pediatric

Segmentation by Distribution Channel
  • Hospital Pharmacies
  • Retail
  • Online


North America has dominated the global inhalers market, and dominance is mainly due to the increase in the prevalence of several respiratory diseases. The US has been the earliest adopters of the latest inhalers technology to reduce the rate of COPD. In North America, both the US and Canada experienced a large-scale adoption of these devices over the last decade. The rise in pollution rates, along with the growing number of cases of respiratory troubles, is one of the major reasons that boosts the overall demand in the region. Besides, since the outbreak of the COVID pandemic, the need for inhalers has grown significantly in ICUs and emergency rooms. A large population on ventilators are supported with inhalers for increased effectiveness of the medicine. Although the market is expected to grow at a slower rate than other regions, there is a surge in demand for inhalers in the region, especially in the US owing to the COVID-19 pandemic. The country will witness growth as the national health spending is projected to grow at an average annual rate of over 5% during the period 2019-2028, reaching $6.2 trillion by 2028.

Segmentation by Geography
  • North America
  • US
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • APAC
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Turkey


The global respiratory inhalers market share is fragmented with the presence of several global, regional, and local vendors offering a wide range of products. GSK, Novartis, BOEHRINGER INGELHEIM, Cipla, and AstraZeneca are the key players dominating the global inhalers market. Although large vendors dominate the market, they are witnessing heavy competition from regional and local companies from India, China, Italy, and Germany. Many regional vendors are also offering cost-effective products in Europe, APAC, and the Middle East & Africa regions.

Prominent Vendors
  • GlaxoSmithKline
  • Novartis
  • Boehringer Ingelheim
  • Cipla
  • AstraZeneca

Other Prominent Vendors
  • Propeller Health
  • Beximco Pharmaceuticals (Beximco Pharma)
  • H&T Presspart
  • Cohero Health
  • CHIESI Farmaceutici
  • Mundipharma
  • 3M
  • HELTMAN Medikal
  • Adherium
  • Luckys Pharma
  • Amiko Digital Health
  • Teva Pharmaceutical Industries
  • Findair Sp.z.o.o
  • Vectura Group


1. What are the respiratory inhalers market size and growth rate during the forecast period?
2. What are the factors impacting the growth of the respiratory inhalers market share?
3. How is the growth of the hospital pharmacies segment influencing the respiratory inhalers market growth?
4. Who are the leading vendors in the respiratory inhalers market, and what are their market shares?
5. What is the impact of the COVID-19 pandemic on the respiratory inhalers market share?

Table of Contents

1 Research Methodology2 Research Objectives3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Product
4.3.2 Market Segmentation by Patient
4.3.3 Market Segmentation by Distribution Channel
4.3.4 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Overview
7.2 Impact Of Covid-19
7.2.1 Overview
8 Market Opportunities & Trends
8.1 Increase In Usage Of Smart Inhaler
8.2 Introduction Of Soft Mist Inhalers
8.3 Surge In Inhalers Usage Due To Covid-19
9 Market Growth Enablers
9.1 Respiratory Inhalers Designed To The Specific Drugs
9.2 Technological Advances In Inhalers
9.3 Increase In Target Population
10 Market Restraints
10.1 Lack Of Awareness And Errors In Usage Of Inhalers
10.2 Challenges In Inhalers Usage
10.3 Global Warming Impacting The Use Of Inhalers
11 Market Landscape
11.1 Market Overview
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat Of New Entrants
11.3.2 Bargaining Power Of Buyers
11.3.3 Bargaining Power Of Suppliers
11.3.4 Threat Of Substitutes
11.3.5 Competitive Rivalry
12 Product
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 Metered Dosage Inhalers
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 Market Snapshot & Growth Engine
12.3.4 Pressurized Metered Dosage Inhalers
12.3.5 Market Overview
12.3.6 Market Size & Forecast
12.3.7 Breath Actuated Mdis
12.3.8 Market Overview
12.3.9 Market Size & Forecast
12.4 Dry Powder Inhalers
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.5 Soft Mist Inhalers
12.5.1 Market Overview
12.5.2 Market Size & Forecast
13 Patient Group
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Pediatric Patients
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.4 Adults
13.4.1 Market Overview
13.4.2 Market Size & Forecast
14 Distribution Channel
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Hospital Pharmacies
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 Retail Pharmacies
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Online
14.5.1 Market Overview
14.5.2 Market Size & Forecast
15 Geography
15.1 Market Snapshot & Growth Engine
15.2 Geographic Overview
16 North America
16.1 Market Overview
16.2 Market Size & Forecast
16.3 Key Countries
16.3.1 US: Market Size & Forecast
16.3.2 Canada: Market Size & Forecast
17 Europe
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Key Countries
17.3.1 UK: Market Size & Forecast
17.3.2 Germany: Market Size & Forecast
17.3.3 France: Market Size & Forecast
17.3.4 Spain: Market Size & Forecast
17.3.5 Italy: Market Size & Forecast
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Key Countries
18.3.1 China: Market Size & Forecast
18.3.2 Japan: Market Size & Forecast
18.3.3 India: Market Size & Forecast
18.3.4 South Korea: Market Size & Forecast
18.3.5 Australia: Market Size & Forecast
19 Latin America
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Key Countries
19.3.1 Brazil: Market Size & Forecast
19.3.2 Mexico: Market Size & Forecast
19.3.3 Argentina: Market Size & Forecast
20 Middle East & Africa
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Key Countries
20.3.1 Turkey: Market Size & Forecast
20.3.2 South Africa: Market Size & Forecast
20.3.3 Saudi Arabia: Market Size & Forecast
21 Competitive Landscape
21.1 Competition Overview
21.2 Market Share Analysis
21.2.1 Cipla
21.2.2 GSK
21.2.3 Novartis
21.2.4 Boehringer Ingelheim
21.2.5 Astrazeneca
22 Key Company Profiles
22.1 Glaxosmithkline
22.1.1 Business Overview
22.1.2 Product Offerings
22.1.3 Key Strategies
22.1.4 Key Strengths
22.1.5 Key Opportunities
22.2 Novartis
22.2.1 Business Overview
22.2.2 Product Offerings
22.2.3 Key Strategies
22.2.4 Key Strengths
22.2.5 Key Opportunities
22.3 Boehringer Ingelheim
22.3.1 Business Overview
22.3.2 Product Offerings
22.3.3 Key Strategies
22.3.4 Key Strengths
22.3.5 Key Opportunities
22.4 Cipla
22.4.1 Business Overview
22.4.2 Product Offerings
22.4.3 Key Strategies
22.4.4 Key Strengths
22.4.5 Key Opportunities
22.5 AstraZeneca
22.5.1 Business Overview
22.5.2 Product Offerings
22.5.3 Key Strategies
22.5.4 Key Strengths
22.5.5 Key Opportunities
23 Other Prominent Vendors
23.1 Propeller Health
23.1.1 Business Overview
23.1.2 Product Offerings
23.2 Beximco Pharmaceuticals
23.2.1 Business Overview
23.2.2 Product Offerings
23.3 H&T Presspart
23.3.1 Business Overview
23.3.2 Product Offerings
23.4 Cohero Health
23.4.1 Business Overview
23.4.2 Product Offerings
23.5 CHIESI Farmaceutici
23.5.1 Business Overview
23.5.2 Product Offerings
23.6 Mundipharma
23.6.1 Business Overview
23.6.2 Product Offerings
23.7 3M
23.7.1 Business Overview
23.7.2 Product Offerings
23.8 HELTMAN Medikal
23.8.1 Business Overview
23.8.2 Product Offerings
23.9 Adherium
23.9.1 Business Overview
23.9.2 Product Offerings
23.10 Luckys Pharma
23.10.1 Business Overview
23.10.2 Product Offerings
23.11 Amiko Digital Health
23.11.1 Business Overview
23.11.2 Product Offerings
23.12 Teva Pharmaceutical Industries
23.12.1 Business Overview
23.12.2 Product Offerings
23.13 Findair Sp. z o. o.
23.13.1 Business Overview
23.13.2 Product Offerings
23.14 Vectura Group
23.14.1 Business Overview
23.14.2 Product Offerings
24 Report Summary
24.1 Key Takeaways
24.2 Strategic Recommendations
25 Quantitative Summary
25.1 Market By Geography
25.2 Market By Patients
25.3 Market By Product
25.4 Market By Distribution Channel
26 Appendix
26.1 Abbreviations

Companies Mentioned

  • GlaxoSmithKline
  • Novartis
  • Boehringer Ingelheim
  • Cipla
  • AstraZeneca
  • Propeller Health
  • Beximco Pharmaceuticals (Beximco Pharma)
  • H&T Presspart
  • Cohero Health
  • CHIESI Farmaceutici
  • Mundipharma
  • 3M
  • HELTMAN Medikal
  • Adherium
  • Luckys Pharma
  • Amiko Digital Health
  • Teva Pharmaceutical Industries
  • Findair Sp.z.o.o
  • Vectura Group


Our research comprises a mix of primary and secondary research. The secondary research sources that are typically referred to include, but are not limited to, company websites, annual reports, financial reports, company pipeline charts, broker reports, investor presentations and SEC filings, journals and conferences, internal proprietary databases, news articles, press releases, and webcasts specific to the companies operating in any given market.

Primary research involves email interactions with the industry participants across major geographies. The participants who typically take part in such a process include, but are not limited to, CEOs, VPs, business development managers, market intelligence managers, and national sales managers. We primarily rely on internal research work and internal databases that we have populated over the years. We cross-verify our secondary research findings with the primary respondents participating in the study.